PrioThera is a ph3 clinical stage pharma company developing a non-immunosuppressive molecule for the treatment of high-risk acute myeloid leukaemia. Mocravimod has been extensively tested in multiple immunological models and has shown a survival benefit and reduced severity of graft-versus-host disease in earlier clinical studies.